A large majority of drug products available in the pharmaceutical market deliver the drug in a non-targeted manner into the human body. The SITE DRUG project is a cross-border approach, dedicated to address the limitations of conventional drug products and overcome sub-optimal treatments through the development of basic science, innovative pharmaceuticals and medical devices for the improvement of patients’ quality of life.
The Interreg 2 Seas SITE DRUG 2020 programme is a Europrean Territorial Cooperation Programme covering England, France, the Netherlands and Belgium (Flanders) and part-financed by the European Regional Development Fund (ERFD).
Through Interreg 2 Seas’s specific objectives incorporating engineering, materials science, medicine, pharmacy, biology, technological innovation and the collaboration of academic research groups will drive towards the fruition of unmet global needs and challenges.
Professor Abdul Basit
Department of Pharmaceutics
UCL School of Pharmacy
Development of innovative pharmaceutical formulations and technologies.
The main objective of the project is to improve the research and translation of pharmaceutical products to optimise current drug delivery systems and disease therapies.
- Innovate drug products
For a safer and more efficient treatment of patients suffering from Crohn’s disease, ulcerative colitis, ovarian cancer, breast resection due to cancer, and hearing loss/deafness.
- Novel in vitro characterisation methods
Facilitating the development of this type of innovative drug delivery systems and assuring adequate quality control during productions.
- Feasibility studies demonstrating the validity of newly developed prototypes
The main target groups are private pharmaceutical companies and medical doctors treating patients suffering from these respective diseases.
SITE DRUG Project Budget Information
Budget: € 4 885 145
Head of Project: University of Lille – Professor Juergen Siepmann - France
Project Partners: University College London (UK), University of Cambridge (UK), Technische Universiteit Delft (NL), Universiteit Leiden (NL), Universitaire de Lille (FR), Universiteit Gent (BE), Lattice Medical (FR), ProDigest (BE), Société d’Accélération du Transfert de Technologie, Nord (FR).
Activities carried out by UCL:
- Development of colon targeting drug delivery technologies
- Driven towards the translation of research into the pharmaceutical market and ultimately, in patients
- Provide enhanced knowhow, network and experience for the overall success of the Interreg 2 Seas 2 Mers project
- Create and develop knowhow, equipment and facilities to manufacture innovative implants for site-specific drug delivery to the inner ear, colon, peritoneal cavity and breast
- Test new prototypes, scale-up the production, translate the obtained new knowledge into practical applications
- Treat patients suffering from the addressed diseases
Duration: 38 months
Official start: 01/01/2020
Find out more: https://www.interreg2seas.eu/en/Site-Drug